Cited 11 times in
Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.